See the DrugPatentWatch profile for Inavolisib
What patent covers inavolisib (and what does “wo patent” imply)?
“Inavolisib” is a drug name used in cancer research. The phrase “wo patent” usually means one of two things: either you want the patent status (whether it’s protected) or you’re asking about “who has the patent” (the assignee/owner). The information needed to answer either way—such as the specific jurisdiction, patent number, or the exact product salt/formulation and use claims—is not provided here.
Which patents usually matter for a drug like inavolisib?
For small-molecule oncology drugs, patent coverage typically comes from a mix of:
- Composition-of-matter patents (protect the molecule itself)
- Method-of-use patents (protect specific therapeutic uses, dosing, or patient subgroups)
- Formulation or process patents (protect specific manufacturing steps or formulations)
Patent status can differ by country, and “inavolisib” may have multiple related families (different applicants and filings).
How long does inavolisib patent protection last (typical timelines)?
Patent life depends on filing date and local rules; the main controlling term is generally 20 years from the earliest priority date for a patent filing, with possible extensions in some jurisdictions (for example, regulatory data/protection extensions). Without the relevant patent filing/priority dates, you can’t calculate an end date for inavolisib specifically.
Who is the patent owner/assignee for inavolisib?
This depends on the particular patent family and jurisdiction. To identify the assignee/owner, you would normally match:
- the exact active ingredient (inavolisib vs. a specific salt),
- the patent family,
- and the jurisdiction (US, EP, JP, etc.).
What to check if you’re trying to find “inavolisib without patent” (generic/biosimilar risk)
If your goal is to know whether a generic could launch “without patent,” the key questions are:
- Does any composition-of-matter patent still exist for the molecule in that country?
- Are there still active method-of-use patents for the approved indication?
- Are there patent expirations staggered across countries?
- Are any patents under litigation, or is there a license/settlement that affects enforceability?
If you want a precise answer, what details should you provide?
To tell you “who has the patent” and whether it’s still protected, share one of the following:
- a patent number, or
- the country (US/EP/JP/etc.) and the drug form/indication you mean, or
- where you saw “wo patent” (a link, screenshot text, or document excerpt)
Reply with the jurisdiction (e.g., “US”) and whether you mean “patent owner” or “expiration,” and I’ll narrow it down to the relevant patent(s).